D
Biogen Inc.
BIIB
$122.98
-$7.73-5.91%
D
Sell
10/31/2024Downgrade
Biogen Inc. (BIIB) was downgraded to D+ from C- on 10/31/2024 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 1.28 to 0.68.
Biogen Inc. (BIIB) was downgraded to D+ from C- on 10/31/2024 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 1.28 to 0.68.
C
Hold
10/14/2024Upgraded
Biogen Inc. (BIIB) was upgraded to C- from D+ on 10/14/2024 due to an increase in the valuation index and volatility index.
Biogen Inc. (BIIB) was upgraded to C- from D+ on 10/14/2024 due to an increase in the valuation index and volatility index.
D
Sell
9/26/2024Downgrade
Biogen Inc. (BIIB) was downgraded to D+ from C- on 9/26/2024 due to a decline in the total return index, volatility index and solvency index.
Biogen Inc. (BIIB) was downgraded to D+ from C- on 9/26/2024 due to a decline in the total return index, volatility index and solvency index.
C
Hold
7/29/2024Upgraded
Biogen Inc. (BIIB) was upgraded to C- from D+ on 7/29/2024 due to an increase in the growth index and volatility index. Operating cash flow increased 4,325.6% from $12.5M to $553.2M, earnings per share increased from $1.7131 to $2.7, and EBIT increased 35.52% from $461.1M to $624.9M.
Biogen Inc. (BIIB) was upgraded to C- from D+ on 7/29/2024 due to an increase in the growth index and volatility index. Operating cash flow increased 4,325.6% from $12.5M to $553.2M, earnings per share increased from $1.7131 to $2.7, and EBIT increased 35.52% from $461.1M to $624.9M.
D
Sell
3/1/2024Downgrade
Biogen Inc. (BIIB) was downgraded to D+ from C- on 3/1/2024 due to a decline in the volatility index.
Biogen Inc. (BIIB) was downgraded to D+ from C- on 3/1/2024 due to a decline in the volatility index.
C
Hold
2/15/2024Upgraded
Biogen Inc. (BIIB) was upgraded to C- from D+ on 2/15/2024 due to an increase in the growth index, solvency index and total return index. Earnings per share increased from -$0.4703 to $1.7131, EBIT increased 70.46% from $270.5M to $461.1M, and the quick ratio increased from 0.98 to 1.04.
Biogen Inc. (BIIB) was upgraded to C- from D+ on 2/15/2024 due to an increase in the growth index, solvency index and total return index. Earnings per share increased from -$0.4703 to $1.7131, EBIT increased 70.46% from $270.5M to $461.1M, and the quick ratio increased from 0.98 to 1.04.
D
Sell
2/13/2024Downgrade
Biogen Inc. (BIIB) was downgraded to D+ from C- on 2/13/2024 due to a decline in the volatility index, efficiency index and valuation index.
Biogen Inc. (BIIB) was downgraded to D+ from C- on 2/13/2024 due to a decline in the volatility index, efficiency index and valuation index.
C
Hold
11/9/2023Downgrade
Biogen Inc. (BIIB) was downgraded to C- from C on 11/9/2023 due to a major decline in the valuation index, total return index and efficiency index. Net income declined 111.51% from $591.6M to -$68.1M.
Biogen Inc. (BIIB) was downgraded to C- from C on 11/9/2023 due to a major decline in the valuation index, total return index and efficiency index. Net income declined 111.51% from $591.6M to -$68.1M.
C
Hold
2/17/2023Downgrade
Biogen Inc. (BIIB) was downgraded to C from C+ on 2/17/2023 due to a noticeable decline in the growth index and efficiency index. Operating cash flow declined 126.48% from $661M to -$175M, earnings per share declined from $7.84 to $3.7974, and net income declined 51.49% from $1.13B to $550.4M.
Biogen Inc. (BIIB) was downgraded to C from C+ on 2/17/2023 due to a noticeable decline in the growth index and efficiency index. Operating cash flow declined 126.48% from $661M to -$175M, earnings per share declined from $7.84 to $3.7974, and net income declined 51.49% from $1.13B to $550.4M.
C
Hold
12/14/2022Upgraded
Biogen Inc. (BIIB) was upgraded to C+ from C on 12/14/2022 due to a large increase in the total return index, valuation index and solvency index. The quick ratio increased from 1.36 to 1.76, and debt to equity declined from 0.61 to 0.49.
Biogen Inc. (BIIB) was upgraded to C+ from C on 12/14/2022 due to a large increase in the total return index, valuation index and solvency index. The quick ratio increased from 1.36 to 1.76, and debt to equity declined from 0.61 to 0.49.
C
Hold
9/30/2022Upgraded
Biogen Inc. (BIIB) was upgraded to C from C- on 9/30/2022 due to an increase in the volatility index and total return index.
Biogen Inc. (BIIB) was upgraded to C from C- on 9/30/2022 due to an increase in the volatility index and total return index.
C
Hold
9/13/2022Downgrade
Biogen Inc. (BIIB) was downgraded to C- from C on 9/13/2022 due to a decline in the total return index.
Biogen Inc. (BIIB) was downgraded to C- from C on 9/13/2022 due to a decline in the total return index.
C
Hold
8/29/2022Upgraded
Biogen Inc. (BIIB) was upgraded to C from C- on 8/29/2022 due to an increase in the volatility index, total return index and valuation index.
Biogen Inc. (BIIB) was upgraded to C from C- on 8/29/2022 due to an increase in the volatility index, total return index and valuation index.
C
Hold
7/21/2022Upgraded
Biogen Inc. (BIIB) was upgraded to C- from D+ on 7/21/2022 due to a significant increase in the growth index, valuation index and efficiency index. Operating cash flow increased 355.19% from $161.8M to $736.5M, earnings per share increased from $2.06 to $7.24, and net income increased 248.26% from $303.8M to $1.06B.
Biogen Inc. (BIIB) was upgraded to C- from D+ on 7/21/2022 due to a significant increase in the growth index, valuation index and efficiency index. Operating cash flow increased 355.19% from $161.8M to $736.5M, earnings per share increased from $2.06 to $7.24, and net income increased 248.26% from $303.8M to $1.06B.
D
Sell
7/13/2022Upgraded
Biogen Inc. (BIIB) was upgraded to D+ from D on 7/13/2022 due to an increase in the total return index and volatility index.
Biogen Inc. (BIIB) was upgraded to D+ from D on 7/13/2022 due to an increase in the total return index and volatility index.
D
Sell
6/27/2022Downgrade
Biogen Inc. (BIIB) was downgraded to D from D+ on 6/27/2022 due to a decline in the volatility index and valuation index.
Biogen Inc. (BIIB) was downgraded to D from D+ on 6/27/2022 due to a decline in the volatility index and valuation index.
D
Sell
5/25/2022Upgraded
Biogen Inc. (BIIB) was upgraded to D+ from D on 5/25/2022 due to an increase in the volatility index and valuation index.
Biogen Inc. (BIIB) was upgraded to D+ from D on 5/25/2022 due to an increase in the volatility index and valuation index.
D
Sell
5/6/2022Downgrade
Biogen Inc. (BIIB) was downgraded to D from D+ on 5/6/2022 due to a decline in the growth index, valuation index and solvency index. Operating cash flow declined 80.7% from $838.3M to $161.8M, earnings per share declined from $2.4981 to $2.06, and total revenue declined 7.39% from $2.73B to $2.53B.
Biogen Inc. (BIIB) was downgraded to D from D+ on 5/6/2022 due to a decline in the growth index, valuation index and solvency index. Operating cash flow declined 80.7% from $838.3M to $161.8M, earnings per share declined from $2.4981 to $2.06, and total revenue declined 7.39% from $2.73B to $2.53B.
D
Sell
4/18/2022Upgraded
Biogen Inc. (BIIB) was upgraded to D+ from D on 4/18/2022 due to an increase in the volatility index.
Biogen Inc. (BIIB) was upgraded to D+ from D on 4/18/2022 due to an increase in the volatility index.
D
Sell
3/31/2022Downgrade
Biogen Inc. (BIIB) was downgraded to D from D+ on 3/31/2022 due to a large decline in the total return index, volatility index and efficiency index.
Biogen Inc. (BIIB) was downgraded to D from D+ on 3/31/2022 due to a large decline in the total return index, volatility index and efficiency index.
D
Sell
11/29/2021Downgrade
Biogen Inc. (BIIB) was downgraded to D+ from C- on 11/29/2021 due to a decline in the total return index and volatility index.
Biogen Inc. (BIIB) was downgraded to D+ from C- on 11/29/2021 due to a decline in the total return index and volatility index.
C
Hold
11/19/2021Downgrade
Biogen Inc. (BIIB) was downgraded to C- from C on 11/19/2021 due to a decline in the volatility index and total return index.
Biogen Inc. (BIIB) was downgraded to C- from C on 11/19/2021 due to a decline in the volatility index and total return index.
C
Hold
11/4/2021Upgraded
Biogen Inc. (BIIB) was upgraded to C from C- on 11/4/2021 due to an increase in the volatility index and total return index.
Biogen Inc. (BIIB) was upgraded to C from C- on 11/4/2021 due to an increase in the volatility index and total return index.
C
Hold
10/15/2021Downgrade
Biogen Inc. (BIIB) was downgraded to C- from C on 10/15/2021 due to a major decline in the valuation index, growth index and volatility index. EBIT declined 46.39% from $940.1M to $504M.
Biogen Inc. (BIIB) was downgraded to C- from C on 10/15/2021 due to a major decline in the valuation index, growth index and volatility index. EBIT declined 46.39% from $940.1M to $504M.
C
Hold
2/9/2021Upgraded
Biogen Inc. (BIIB) was upgraded to C from C- on 2/9/2021 due to an increase in the volatility index, efficiency index and solvency index. Total capital increased 0.1% from $18.58B to $18.6B.
Biogen Inc. (BIIB) was upgraded to C from C- on 2/9/2021 due to an increase in the volatility index, efficiency index and solvency index. Total capital increased 0.1% from $18.58B to $18.6B.
C
Hold
2/1/2021Downgrade
Biogen Inc. (BIIB) was downgraded to C- from C on 2/1/2021 due to a decline in the volatility index and valuation index.
Biogen Inc. (BIIB) was downgraded to C- from C on 2/1/2021 due to a decline in the volatility index and valuation index.
C
Hold
1/11/2021Upgraded
Biogen Inc. (BIIB) was upgraded to C from C- on 1/11/2021 due to an increase in the volatility index.
Biogen Inc. (BIIB) was upgraded to C from C- on 1/11/2021 due to an increase in the volatility index.
C
Hold
12/21/2020Downgrade
Biogen Inc. (BIIB) was downgraded to C- from C on 12/21/2020 due to a substantial decline in the growth index, total return index and solvency index. Earnings per share declined from $9.59 to $4.46, EBIT declined 46.12% from $2B to $1.08B, and operating cash flow declined 39.38% from $1.95B to $1.18B.
Biogen Inc. (BIIB) was downgraded to C- from C on 12/21/2020 due to a substantial decline in the growth index, total return index and solvency index. Earnings per share declined from $9.59 to $4.46, EBIT declined 46.12% from $2B to $1.08B, and operating cash flow declined 39.38% from $1.95B to $1.18B.
C
Hold
6/18/2020Downgrade
Biogen Inc. (BIIB) was downgraded to C from C+ on 6/18/2020 due to a decline in the volatility index and total return index.
Biogen Inc. (BIIB) was downgraded to C from C+ on 6/18/2020 due to a decline in the volatility index and total return index.
C
Hold
5/28/2020Downgrade
Biogen Inc. (BIIB) was downgraded to C+ from B- on 5/28/2020 due to a decline in the total return index and valuation index.
Biogen Inc. (BIIB) was downgraded to C+ from B- on 5/28/2020 due to a decline in the total return index and valuation index.
B
Buy
5/8/2020Upgraded
Biogen Inc. (BIIB) was upgraded to B- from C+ on 5/8/2020 due to an increase in the total return index, growth index and solvency index. EBIT increased 9.74% from $1.72B to $1.89B.
Biogen Inc. (BIIB) was upgraded to B- from C+ on 5/8/2020 due to an increase in the total return index, growth index and solvency index. EBIT increased 9.74% from $1.72B to $1.89B.
C
Hold
4/13/2020Upgraded
Biogen Inc. (BIIB) was upgraded to C+ from C on 4/13/2020 due to a major increase in the total return index, volatility index and efficiency index.
Biogen Inc. (BIIB) was upgraded to C+ from C on 4/13/2020 due to a major increase in the total return index, volatility index and efficiency index.
C
Hold
10/30/2019Upgraded
Biogen Inc. (BIIB) was upgraded to C from C- on 10/30/2019 due to an increase in the volatility index, growth index and valuation index. Earnings per share increased from $7.85 to $8.39.
Biogen Inc. (BIIB) was upgraded to C from C- on 10/30/2019 due to an increase in the volatility index, growth index and valuation index. Earnings per share increased from $7.85 to $8.39.
C
Hold
5/15/2019Downgrade
Biogen Inc. (BIIB) was downgraded to C- from C on 5/15/2019 due to a noticeable decline in the total return index and volatility index.
Biogen Inc. (BIIB) was downgraded to C- from C on 5/15/2019 due to a noticeable decline in the total return index and volatility index.
C
Hold
4/3/2019Downgrade
Biogen Inc. (BIIB) was downgraded to C from C+ on 4/3/2019 due to a decline in the volatility index and total return index.
Biogen Inc. (BIIB) was downgraded to C from C+ on 4/3/2019 due to a decline in the volatility index and total return index.
C
Hold
3/29/2019Downgrade
Biogen Inc. (BIIB) was downgraded to C+ from B- on 3/29/2019 due to a noticeable decline in the volatility index.
Biogen Inc. (BIIB) was downgraded to C+ from B- on 3/29/2019 due to a noticeable decline in the volatility index.
B
Buy
2/25/2019Upgraded
Biogen Inc. (BIIB) was upgraded to B- from C+ on 2/25/2019 due to a noticeable increase in the valuation index, volatility index and growth index. Operating cash flow increased 9.19% from $1.74B to $1.9B, and total revenue increased 2.54% from $3.44B to $3.53B.
Biogen Inc. (BIIB) was upgraded to B- from C+ on 2/25/2019 due to a noticeable increase in the valuation index, volatility index and growth index. Operating cash flow increased 9.19% from $1.74B to $1.9B, and total revenue increased 2.54% from $3.44B to $3.53B.
C
Hold
1/3/2019Downgrade
Biogen Inc. (BIIB) was downgraded to C+ from B- on 1/3/2019 due to a decline in the total return index.
Biogen Inc. (BIIB) was downgraded to C+ from B- on 1/3/2019 due to a decline in the total return index.
B
Buy
12/3/2018Upgraded
Biogen Inc. (BIIB) was upgraded to B- from C+ on 12/3/2018 due to an increase in the volatility index.
Biogen Inc. (BIIB) was upgraded to B- from C+ on 12/3/2018 due to an increase in the volatility index.
C
Hold
10/29/2018Upgraded
Biogen Inc. (BIIB) was upgraded to C+ from C on 10/29/2018 due to a large increase in the volatility index, growth index and total return index. Earnings per share increased from $4.18 to $7.15, operating cash flow increased 57.91% from $1.1B to $1.74B, and EBIT increased 41.26% from $1.33B to $1.88B.
Biogen Inc. (BIIB) was upgraded to C+ from C on 10/29/2018 due to a large increase in the volatility index, growth index and total return index. Earnings per share increased from $4.18 to $7.15, operating cash flow increased 57.91% from $1.1B to $1.74B, and EBIT increased 41.26% from $1.33B to $1.88B.
C
Hold
4/26/2018Upgraded
Biogen Inc. (BIIB) was upgraded to C from C- on 4/26/2018 due to a significant increase in the growth index, valuation index and solvency index. Earnings per share increased from -$1.4087 to $5.54, the quick ratio increased from 1.78 to 2.67, and debt to equity declined from 0.47 to 0.42.
Biogen Inc. (BIIB) was upgraded to C from C- on 4/26/2018 due to a significant increase in the growth index, valuation index and solvency index. Earnings per share increased from -$1.4087 to $5.54, the quick ratio increased from 1.78 to 2.67, and debt to equity declined from 0.47 to 0.42.
C
Hold
3/23/2018Downgrade
Biogen Inc. (BIIB) was downgraded to C- from C on 3/23/2018 due to a noticeable decline in the volatility index and total return index.
Biogen Inc. (BIIB) was downgraded to C- from C on 3/23/2018 due to a noticeable decline in the volatility index and total return index.
C
Hold
2/2/2018Downgrade
Biogen Inc. (BIIB) was downgraded to C from B- on 2/2/2018 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $5.79 to -$1.4087, net income declined 124.26% from $1.23B to -$297.4M, and EBIT declined 9.95% from $1.72B to $1.55B.
Biogen Inc. (BIIB) was downgraded to C from B- on 2/2/2018 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $5.79 to -$1.4087, net income declined 124.26% from $1.23B to -$297.4M, and EBIT declined 9.95% from $1.72B to $1.55B.
B
Buy
1/12/2018Upgraded
Biogen Inc. (BIIB) was upgraded to B- from C+ on 1/12/2018 due to an increase in the total return index and volatility index.
Biogen Inc. (BIIB) was upgraded to B- from C+ on 1/12/2018 due to an increase in the total return index and volatility index.
C
Hold
12/28/2017Downgrade
Biogen Inc. (BIIB) was downgraded to C+ from B- on 12/28/2017 due to a decline in the total return index and valuation index.
Biogen Inc. (BIIB) was downgraded to C+ from B- on 12/28/2017 due to a decline in the total return index and valuation index.
B
Buy
12/13/2017Upgraded
Biogen Inc. (BIIB) was upgraded to B- from C+ on 12/13/2017 due to an increase in the total return index, valuation index and volatility index.
Biogen Inc. (BIIB) was upgraded to B- from C+ on 12/13/2017 due to an increase in the total return index, valuation index and volatility index.
C
Hold
10/23/2017Upgraded
Biogen Inc. (BIIB) was upgraded to C+ from C on 10/23/2017 due to an increase in the efficiency index, total return index and volatility index. Net income increased 15.41% from $747.6M to $862.8M, and total capital increased 0.59% from $17.98B to $18.09B.
Biogen Inc. (BIIB) was upgraded to C+ from C on 10/23/2017 due to an increase in the efficiency index, total return index and volatility index. Net income increased 15.41% from $747.6M to $862.8M, and total capital increased 0.59% from $17.98B to $18.09B.
C
Hold
1/9/2017Downgrade
Biogen Inc. (BIIB) was downgraded to C from C+ on 1/9/2017 due to a noticeable decline in the total return index and volatility index.
Biogen Inc. (BIIB) was downgraded to C from C+ on 1/9/2017 due to a noticeable decline in the total return index and volatility index.
C
Hold
10/28/2016Downgrade
Biogen Inc. (BIIB) was downgraded to C+ from B- on 10/28/2016 due to a decline in the growth index and efficiency index. Earnings per share declined from $4.79 to $4.71, net income declined 1.61% from $1.05B to $1.03B, and EBIT declined 1.59% from $1.49B to $1.46B.
Biogen Inc. (BIIB) was downgraded to C+ from B- on 10/28/2016 due to a decline in the growth index and efficiency index. Earnings per share declined from $4.79 to $4.71, net income declined 1.61% from $1.05B to $1.03B, and EBIT declined 1.59% from $1.49B to $1.46B.
B
Buy
10/27/2016Upgraded
Biogen Inc. (BIIB) was upgraded to B- from C+ on 10/27/2016 due to a noticeable increase in the total return index, valuation index and volatility index.
Biogen Inc. (BIIB) was upgraded to B- from C+ on 10/27/2016 due to a noticeable increase in the total return index, valuation index and volatility index.
C
Hold
8/29/2016Upgraded
Biogen Inc. (BIIB) was upgraded to C+ from C on 8/29/2016 due to an increase in the growth index, volatility index and solvency index. The quick ratio increased from 1.91 to 2.16, debt to equity declined from 0.63 to 0.57, and earnings per share increased from $4.43 to $4.79.
Biogen Inc. (BIIB) was upgraded to C+ from C on 8/29/2016 due to an increase in the growth index, volatility index and solvency index. The quick ratio increased from 1.91 to 2.16, debt to equity declined from 0.63 to 0.57, and earnings per share increased from $4.43 to $4.79.
C
Hold
4/11/2016Downgrade
Biogen Inc. (BIIB) was downgraded to C from C+ on 4/11/2016 due to a decline in the volatility index, total return index and valuation index.
Biogen Inc. (BIIB) was downgraded to C from C+ on 4/11/2016 due to a decline in the volatility index, total return index and valuation index.
C
Hold
3/11/2016Downgrade
Biogen Inc. (BIIB) was downgraded to C+ from B on 3/11/2016 due to a large decline in the volatility index.
Biogen Inc. (BIIB) was downgraded to C+ from B on 3/11/2016 due to a large decline in the volatility index.
B
Buy
3/7/2016Upgraded
Biogen Inc. (BIIB) was upgraded to B from B- on 3/7/2016 due to an increase in the volatility index, valuation index and efficiency index.
Biogen Inc. (BIIB) was upgraded to B from B- on 3/7/2016 due to an increase in the volatility index, valuation index and efficiency index.
B
Buy
1/12/2016Downgrade
Biogen Inc. (BIIB) was downgraded to B- from B on 1/12/2016 due to a decline in the total return index.
Biogen Inc. (BIIB) was downgraded to B- from B on 1/12/2016 due to a decline in the total return index.
B
Buy
12/28/2015Upgraded
Biogen Inc. (BIIB) was upgraded to B from B- on 12/28/2015 due to an increase in the total return index.
Biogen Inc. (BIIB) was upgraded to B from B- on 12/28/2015 due to an increase in the total return index.
B
Buy
10/13/2015Downgrade
Biogen Inc. (BIIB) was downgraded to B- from B on 10/13/2015 due to a noticeable decline in the volatility index and total return index.
Biogen Inc. (BIIB) was downgraded to B- from B on 10/13/2015 due to a noticeable decline in the volatility index and total return index.
B
Buy
10/5/2015Downgrade
Biogen Inc. (BIIB) was downgraded to B from B+ on 10/5/2015 due to a decline in the volatility index and total return index.
Biogen Inc. (BIIB) was downgraded to B from B+ on 10/5/2015 due to a decline in the volatility index and total return index.
B
Buy
9/28/2015Downgrade
Biogen Inc. (BIIB) was downgraded to B+ from A- on 9/28/2015 due to a significant decline in the volatility index and total return index.
Biogen Inc. (BIIB) was downgraded to B+ from A- on 9/28/2015 due to a significant decline in the volatility index and total return index.
A
Buy
7/24/2015Upgraded
Biogen Inc. (BIIB) was upgraded to A- from B+ on 7/24/2015 due to an increase in the growth index, valuation index and efficiency index. Operating cash flow increased 42.86% from $733.04M to $1.05B, net income increased 12.73% from $822.54M to $927.28M, and earnings per share increased from $3.49 to $3.93.
Biogen Inc. (BIIB) was upgraded to A- from B+ on 7/24/2015 due to an increase in the growth index, valuation index and efficiency index. Operating cash flow increased 42.86% from $733.04M to $1.05B, net income increased 12.73% from $822.54M to $927.28M, and earnings per share increased from $3.49 to $3.93.
B
Buy
7/6/2015Downgrade
Biogen Inc. (BIIB) was downgraded to B+ from A- on 7/6/2015 due to a decline in the growth index. Operating cash flow declined 21.42% from $932.86M to $733.04M, earnings per share declined from $3.734 to $3.49, and total revenue declined 3.23% from $2.64B to $2.55B.
Biogen Inc. (BIIB) was downgraded to B+ from A- on 7/6/2015 due to a decline in the growth index. Operating cash flow declined 21.42% from $932.86M to $733.04M, earnings per share declined from $3.734 to $3.49, and total revenue declined 3.23% from $2.64B to $2.55B.
A
Buy
1/27/2015Upgraded
Biogen Idec Inc. (BIIB) was upgraded to A- from B+ on 1/27/2015 due to an increase in the total return index.
Biogen Idec Inc. (BIIB) was upgraded to A- from B+ on 1/27/2015 due to an increase in the total return index.
B
Buy
12/10/2014Downgrade
Biogen Idec Inc. (BIIB) was downgraded to B+ from A- on 12/10/2014 due to a decline in the volatility index and growth index. Operating cash flow declined 7.73% from $990.59M to $914.03M.
Biogen Idec Inc. (BIIB) was downgraded to B+ from A- on 12/10/2014 due to a decline in the volatility index and growth index. Operating cash flow declined 7.73% from $990.59M to $914.03M.
A
Buy
7/25/2014Upgraded
Biogen Idec Inc. (BIIB) was upgraded to A- from B on 7/25/2014 due to an increase in the growth index, valuation index and solvency index. Operating cash flow increased 846.79% from $104.63M to $990.59M, earnings per share increased from $2.02 to $3.01, and EBIT increased 40.98% from $701.39M to $988.84M.
Biogen Idec Inc. (BIIB) was upgraded to A- from B on 7/25/2014 due to an increase in the growth index, valuation index and solvency index. Operating cash flow increased 846.79% from $104.63M to $990.59M, earnings per share increased from $2.02 to $3.01, and EBIT increased 40.98% from $701.39M to $988.84M.
B
Buy
7/11/2014Downgrade
Biogen Idec Inc. (BIIB) was downgraded to B from B+ on 7/11/2014 due to a decline in the valuation index and total return index.
Biogen Idec Inc. (BIIB) was downgraded to B from B+ on 7/11/2014 due to a decline in the valuation index and total return index.
B
Buy
6/3/2014Downgrade
Biogen Idec Inc. (BIIB) was downgraded to B+ from A- on 6/3/2014 due to a large decline in the total return index and growth index. Operating cash flow declined 87.96% from $869.01M to $104.63M.
Biogen Idec Inc. (BIIB) was downgraded to B+ from A- on 6/3/2014 due to a large decline in the total return index and growth index. Operating cash flow declined 87.96% from $869.01M to $104.63M.
NASDAQ
04/04/2025 4:00PM Eastern
Quotes delayed
